NurOwn is a stem cell therapy developed by BrainStorm Cell Therapeutics Inc. for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. NurOwn involves the use of mesenchymal stem cells (MSCs) derived from the patient's own bone marrow, which are then modified to produce high levels of neurotrophic factors (NTFs) that support the survival and function of neurons.
Regarding the cost of NurOwn treatment, it is important to note that stem cell therapies are generally expensive due to the complex processes involved in cell harvesting, culturing, and administration. The exact cost of NurOwn treatment can vary depending on several factors, including the location of the treatment center, the number of treatments required, and the patient's insurance coverage.
As of the knowledge cutoff date in April 2023, NurOwn was still in the clinical trial phase, and its commercial availability and pricing were not yet established. If and when NurOwn receives regulatory approval and becomes commercially available, the cost will be determined by the manufacturer and may be subject to negotiation with healthcare providers and insurers.
Patients interested in NurOwn or any other stem cell therapy should consult with their healthcare providers and consider the potential out-of-pocket expenses, as well as the availability of insurance coverage or financial assistance programs. It is also advisable to inquire directly with the treatment center or the therapy's developer for the most up-to-date information on costs and availability.
